Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia
Venetoclax联合gilteritinib在FLT3突变型BCL11B-a谱系不明确白血病的临床前模型中有效。
期刊:Blood
影响因子:21
doi:10.1182/blood.2025028985.
Lindsey E Montefiori,Ilaria Iacobucci,Qingsong Gao,Jamila Moore,William C Wright,Huimei Wei,Pradyumna Baviskar,Surbhi Sona,Hongjian Jin,Amit Budhraja,Josi Lott,Qi Zhang Tatarata,Zhongshan Cheng,Tanya Khan,Emily A Backhaus Wagner,Melissa Johnson,Cyrus M Mehr,Burgess Freeman,Laura Janke,Torsten Haferlach,Paul Geeleher,Paul E Mead,Marina Konopleva,Joseph T Opferman,Charles G Mullighan